These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 22980700)

  • 1. Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia.
    Lu L; Peters J; Roome C; Stein K
    Int J Technol Assess Health Care; 2012 Jul; 28(3):241-8. PubMed ID: 22980700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
    Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP
    J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial.
    Purmonen TT; Pänkäläinen E; Turunen JH; Asseburg C; Martikainen JA
    Acta Oncol; 2011 Apr; 50(3):344-52. PubMed ID: 21299447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
    Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
    Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.
    Damlaj M; Sulai NH; Oliveira JL; Ketterling RP; Hashmi S; Witzig T; Nowakowski G; Call TG; Shanafelt TD; Ding W; Hogan WJ; Litzow MR; Patnaik MM
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):699-704. PubMed ID: 26422251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada.
    Hedden L; Kennecke H; Villa D; Johnston K; Speers C; Kovacic L; Renouf DJ; Peacock S
    Eur J Cancer; 2012 Sep; 48(13):1969-76. PubMed ID: 22325838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
    Montero AJ; Avancha K; Glück S; Lopes G
    Breast Cancer Res Treat; 2012 Apr; 132(2):747-51. PubMed ID: 22200867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
    O'Day K; Meyer K; Miller RM; Agarwal S; Franklin M
    J Med Econ; 2011; 14(5):617-27. PubMed ID: 21777161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
    Lu L; Peters J; Roome C; Stein K
    BJU Int; 2012 Apr; 109(8):1183-92. PubMed ID: 21883830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
    Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
    Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
    Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case report of T cell prolymphocytic leukemia and Kaposi sarcoma and a review of T cell prolymphocytic leukemia.
    Paul RN; Alizadeh L; Ajayi OI; Karpurapu H; Ganesan C; Taddesse-Heath L; Aggarwal A
    Acta Haematol; 2012; 127(4):235-43. PubMed ID: 22517037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-effectiveness analysis of Belimumab in patients with systemic lupus erythematosus in Spain].
    Díaz-Cerezo S; García-Aparicio ÁM; Parrondo J; Vallejo-Aparicio LA
    Farm Hosp; 2015 May; 39(3):161-70. PubMed ID: 26005892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Successful Treatment of T-Cell Prolymphocytic Leukemia with Alemtuzumab].
    Ueki D; Yoshida C; Tsutsumi Oota I; Seki M; Komeno T; Ito H; Ide Y
    Gan To Kagaku Ryoho; 2019 May; 46(5):913-915. PubMed ID: 31189814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell prolymphocytic leukemia: A rare disease in an elderly female.
    Madaris L
    J Am Acad Nurse Pract; 2010 Dec; 22(12):648-53. PubMed ID: 21129072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell prolymphocytic leukaemia (T-PLL): a rare disease with a grave prognosis.
    Vivekanandarajah A; Atallah JP; Gupta S
    BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23645660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coronary vasculitis associated with T-cell prolymphocytic leukemia.
    Audemard A; Boutemy J; Guilpain P; Sabatier R; Silva NM; Bienvenu B
    Joint Bone Spine; 2014 Jan; 81(1):93-4. PubMed ID: 23731632
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.